The U.S. Food and Drug Administration (FDA) has approved two tests to identify genetic alterations in tumors. These tests, which are done on a tumor sample, look for hundreds of known genetic mutations and alterations linked to cancer. The results can potentially be used to make treatment decisions.
Genomic tumor testing is currently not the standard of care for breast cancer patients–but one day it might be. Below you can read about the two tests.
- National Cancer Institute: FDA Clears Two Genomic Tests
- Practice Update (free registration is required to read the article): Current Concepts in Genomic Profiling for Breast Cancer
- Clinical Cancer Research: Expanded Profiling in MBC
- OncLive: Molecular Profiling Not Yet Standard of Care for MBC
- Metastatic Trial Search: Find Metastatic Breast Cancer Trials with Genomic Testing
Last Modified on March 4, 2021
Tags:Genetics & GenomicsScreening and TestingInside Clinical Trials